'DURVIT': Single low-dose DURValumab IntraTumorally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment.
Phase of Trial: Phase I
Latest Information Update: 03 Jan 2018
At a glance
- Drugs Durvalumab (Primary)
- Indications Cervical cancer
- Focus Adverse reactions
- Acronyms DURVIT
- 29 Dec 2017 Status changed from not yet recruiting to recruiting.
- 29 Dec 2017 Planned initiation date changed from 1 Dec 2017 to 30 Nov 2017.
- 29 Dec 2017 Planned number of patients changed from 12 to 24.